Harvard Bioscience (HBIO) Payables (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Payables data on file, last reported at $5.3 million in Q1 2026.

• On a quarterly basis, Payables rose 9.96% year-over-year to $5.3 million in Q1 2026; TTM through Mar 2026 was $5.3 million, a 9.96% increase from a year earlier, with the FY2025 full-year figure at $3.7 million, down 23.71% from the prior year.
• Payables for Q1 2026 stood at $5.3 million, up from $3.7 million in the prior quarter.
• Over the last five years, Payables for HBIO reached as high as $6.8 million in Q2 2022 and fell as low as $3.7 million in Q4 2025.
• Historically, Payables has averaged $5.5 million across 5 years, with a median of $5.6 million in 2023.
• Across the five-year window, Payables surged 31.28% in 2022 and tumbled 30.75% in 2023, its largest moves.
• Year by year, Payables stood at $6.4 million in 2022, then declined by 13.85% to $5.6 million in 2023, then dropped by 13.81% to $4.8 million in 2024, then retreated by 23.71% to $3.7 million in 2025, then surged by 44.77% to $5.3 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $5.3 million in Q1 2026, $3.7 million in Q4 2025, and $5.2 million in Q3 2025.